Making a Case for Albumin – a Highly Promising Drug-Delivery System

References

• Peters T . All About Albumin: Biochemistry, Genetics and Medical Applications.Academic Press Inc, California, USA (1996).
   Google Scholar
• Merlot AM , KalinowskiDS, RichardsonDR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol.5, 299 (2014).
   PubMed Web of Science ®Google Scholar
• Vincent JL . Relevance of albumin in modern critical care medicine. Best Pract. Res. Clin. Anaesthesiol.23 (2), 183–191 (2009).
   PubMedGoogle Scholar
• Aguirre Puig P , Orallo MoranMA, Pereira MatalobosD, Prieto RequeijoP. Current role of albumin in critical care. Rev. Esp. Anestesiol. Reanim.61 (9), 497–504 (2014).
   PubMedGoogle Scholar
• Kratz F . Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release132 (3), 171–183 (2008).
   PubMed Web of Science ®Google Scholar
• Kratz F , ElsadekB. Clinical impact of serum proteins on drug delivery. J. Control. Release161 (2), 429–445 (2012).
   PubMed Web of Science ®Google Scholar
• Kratz F . A clinical update of using albumin as a drug vehicle – a commentary. J. Control. Release190, 331–336 (2014).
   PubMed Web of Science ®Google Scholar
• Iyer AK , KhaledG, FangJ, MaedaH. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today11 (17–18), 812–818 (2006).
   PubMed Web of Science ®Google Scholar
• Poon K , KingAB. Glargine and detemir: safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc. Patient Saf.2, 213–223 (2010).
   PubMedGoogle Scholar
• Haahr H , HeiseT. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin. Pharmacokinet.53 (9), 787–800 (2014).
   PubMed Web of Science ®Google Scholar
• Garg SK . The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes—a comprehensive review. Diabetes Technol. Ther.12 (1), 11–24 (2010).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM , De BruynS, DubyCet al. A Novel individualized treatment approach in open-label extension study of ozoralizumab (ATN-103) in subjects with rheumatoid arthritis on a background of methotrexate. Arthritis Rheum.64 (10), S563 (2012).
   Google Scholar
• Socinski MA , BondarenkoI, KarasevaNAet al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J. Clin. Oncol.30 (17), 2055–2062 (2012).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ , TjulandinS, DavidsonNet al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol.23 (31), 7794–7803 (2005).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . NCT01730586 (2012).
   Google Scholar
• ClinicalTrials.gov . NCT00583349 (2007).
   Google Scholar
• ClinicalTrials.gov . NCT00995488 (2009).
   Google Scholar
• ClinicalTrials.gov . NCT01827111 (2013).
   Google Scholar
• ClinicalTrials.gov . NCT00731380 (2008).
   Google Scholar
• ClinicalTrials.gov . NCT01307891 (2011).
   Google Scholar
• Graeser R , EsserN, UngerHet al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared with doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest. New Drugs28 (1), 14–19 (2010).
   PubMed Web of Science ®Google Scholar
• Mcdonagh CF , HuhalovA, HarmsBDet al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther.11 (3), 582–593 (2012).
   PubMed Web of Science ®Google Scholar
• Vis AN , Van Der GaastA, Van RhijnBW, CatsburgTK, SchmidtC, MickischGH. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy. Cancer Chemother. Pharmacol.49 (4), 342–345 (2002).
   PubMed Web of Science ®Google Scholar
• Bolling C , GraefeT, LubbingCet al. Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest. New Drugs24 (6), 521–527 (2006).
   PubMed Web of Science ®Google Scholar
• Flisiak R , FlisiakI. Albinterferon-alpha 2b: a new treatment option for hepatitis C. Expert Opin. Biol. Ther.10 (10), 1509–1515 (2010).
   PubMed Web of Science ®Google Scholar
• Merlot AM , SahniS, LaneDJRet al. Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells. Oncotarget (2015) ( In Press).
   Google Scholar